Huntington Valley, PA, USA) is the only system approved for clinical use. 6 CellSearch is an automated system to isolate CTCs using an Ab against EpCAM that is abundantly expressed on epithelial cells. 6, 7 CellSearch has provided highly reproducible results in detection of CTCs, 6 and has been approved to monitor peripheral blood of patients with metastatic breast, prostate, and colorectal cancer in the USA.
Malignant pleural mesothelioma is a highly aggressive malignant tumor originating from the mesothelium. [8] [9] [10] To evaluate the clinical utility of CTCs detected with CellSearch in MPM, we undertook a prospective study. 11 The CTC test provided significant diagnostic performance in discrimination between MPM and nonmalignant pleural diseases such as asbestos pleurisy (P = .036).
However, CTCs were detected only in 32.7% (34/104) of MPM patients, and the low sensitivity could mainly be due to EpCAMdependent capture of CTCs in CellSearch. Malignant pleural mesothelioma cells of mesothelial origin, not of epithelial origin, showed negative or low EpCAM expression, which might not be effectively captured with CellSearch. 11 These results indicate a need for a more sensitive system to detect CTCs that can capture EpCAM-negative tumor cells. Accordingly, we have developed a novel microfluidic device system in which CTCs are captured to numerous microposts coated with an Ab against an antigen expressed on target tumor cells (CTC-chip). 12, 13 The most important advantage of the novel CTC-chip system is its capability of conjugating any Ab to capture CTCs ("universal" CTC-chip), which could enable capture of a wide variety of CTCs by conjugating appropriate Abs. In fact, our previous experimental studies showed that MPM tumor cells were captured with the CTC-chip coated with an Ab against podoplanin that was abundantly expressed on mesothelial cells. 13, 14 However, the capture efficacy of tumor cells spiked in the blood remains less than 40%, 13 which might not be enough for clinical application.
In the present study, we improved the capture efficiency up to 80% by optimizing conditions in preparing the CTC-chip for capturing MPM cells, which provided an overwhelmingly higher performance than CellSearch. In addition, the CTC test showed a significant diagnostic performance in discrimination between early disease and advanced disease, and also provided a significant prognostic value in MPM. The novel CTC-chip is the first promising system to detect CTCs that can be applied for clinical use in the diagnosis and treatment of MPM.
| MATERIAL S AND ME THODS

| Cell lines
Human mesothelioma cell line ACC-MESO-4 was purchased from the Riken BioResource Center (Tsukuba, Japan), and H226, H28, and MSTO-211H were from ATCC (Manassas, VA, USA). These cells were cultured in RPMI-1640 medium (Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% FBS (Invitrogen, San Diego, CA, USA) at 37°C and 5% CO 2 . 
| Flow cytometry
| Preparation of CTC-chip
The CTC-chip system was used after 2-step coating with an Ab to capture CTCs as described previously ( Figure S1 ). 13 In brief, the chip was first incubated with a goat anti-mouse IgG Ab (SouthernBiotech, Birmingham, AL, USA) overnight at 4°C. Thereafter, the chip was incubated with an antipodoplanin Ab (clone E1) to capture tumor cells for 1 hour at 4°C (podoplanin-chip). After washing with PBS, the chip surface was kept wet.
In previous studies, both the concentration of the "base antibody" (anti-mouse IgG Ab) coated over the chip surface and that of the "capture antibody" (antipodoplanin Ab) conjugated to the base Ab to capture tumor cells were 20 μg/mL. 13 In the present study, higher concentrations of these Abs were tested to improve the cellcapture efficacy ( Figure S1 ).
| Cell-capture efficacy of CTC-chip
Sample preparation and flow test to evaluate cell-capture efficiency were carried out as described previously. 13 In brief, tumor cells were 
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Experiments were carried out in triplicate. Circulating tumor cells were quantitatively evaluated as described previously. 6, 7 The number of CTCs in 1 mL blood was indicated as the CTC count for the CTC-chip, and that in 7.5 mL blood was indicated as the CTC count for CellSearch.
The revised TNM criteria were used for evaluation of tumor staging. 15 Podoplanin expression on tumor cells in pathological sections was evaluated with immunohistochemical staining using an antipodoplanin Ab (D2-40; Nichirei Biosciences, Tokyo, Japan). This study was approved by the Ethics Committee of Medical Research, University of Occupational and Environmental Health (Kitakyushu, Japan).
| Statistical analyses
The proportions of categorical data were compared by the χ 2 test. Continuous data were compared using a nonparametric test (Mann-Whitney U test). The Kaplan-Meier method was used to estimate the probability of survival, with survival differences being
analyzed by the log-rank test. Differences were considered to be statistically significant for P-value <.05. All statistical analyses were carried out with SPSS version 21 software (IBM, Armonk, NY, USA). shown in the previous study. 13 When the base-Ab concentration was increased to 200 μg/mL, the cell-capture efficiency improved (average capture efficiency, 84.1%). However, even when a higher concentration (500 μg/mL) of base-Ab was used in combination with a higher concentration of capture-Ab (500 μg/mL), no higher cell- Overall, the CTC-positivity was significantly higher with the CTCchip than with CellSearch (68.5% vs 6.3%, P < .001).
| RE SULTS
| Improvement in cell-capture efficiency at higher Ab concentrations
| Clinical implications of CTCs detected with the CTC-chip
To evaluate the clinical implications of CTCs detected with the podoplanin-chip, we further analyzed additional blood samples drawn from a total of 25 patients with MPM ( disease; P = .003) ( Figure 5 ). As stage IIIB and IV diseases are generally recognized as "unresectable" disease, a ROC curve analysis was F I G U R E 2 Cell-capture efficacy for several mesothelioma cell lines using a novel microfluidic device to capture rare tumor cells circulating in the blood, the CTC-chip. Several mesothelioma cells (ACC-MESO-4, H226, H28, and MSTO-211H) were spiked in the blood sampled from a healthy volunteer. The cell suspension (100 cells/mL) was applied to the optimized podoplanin-chip (base-Ab concentration, 200 μg/mL; capture-Ab concentration, 20 μg/mL). Podoplanin expression on each cell line was examined with flow cytometry, and the percentage of positive cells and the mean fluorescence intensity (MFI) are indicated. Experiments were carried out in triplicate. Error bar shows SD carried out to determine the optimal cut-off value of CTC count in discrimination between "unresectable" disease (stage IIIB or IV disease) and "resectable" disease (stage IIIA or earlier). The area under ROC curve was 0.851 (95% confidence interval, 0.667-1.000), indicating a significant diagnostic performance of the CTC-test to predict "unresectable" disease in MPM (P = .003; Figure 5 ). The optimal cut-off value of the CTC-count was estimated as "2" which provided a very high specificity (90.9%) with a moderate sensitivity (64.3%).
When the cut-off value of "1" was used, the sensitivity was higher (92.3%) but the specificity was modest (72.7%). When patients were classified into high-CTC and low-CTC patients according to the cutoff value of 2, high-CTC (CTC-count ≥2) was significantly associated with a poor prognosis ( Figure 5 ).
The CTC-count was longitudinally monitored during treatment in 2 patients. In both patients, the CTC-count decreased after effective treatment (curative surgery followed by adjuvant chemotherapy in Case 1 or chemotherapy in Case 2; Figure S3 ).
| D ISCUSS I ON
In the present study, we first optimized the novel CTC-chip for effective capture of MPM cells by using higher concentrations of Among a variety of EpCAM-independent methods including sizebased or density-based separation, 1-3 we adopted a microfluidic method (CTC-chip). The original CTC-chip, which was conjugated with an anti-EpCAM Ab, could capture only EpCAM-positive tumor cells. 16 To overcome its EpCAM-dependent limitations, we have developed a novel CTC-chip to which any capture-Ab can be easily conjugated. 12, 13 In the present study, we optimized the CTC- We also indicated significant clinical relevance of CTCs detected with the CTC-chip. The CTC count was significantly higher in advanced and "unresectable" stages (IIIB or IV) of disease, which provided a significant diagnostic performance to discriminate patients with unresectable disease from those with resectable disease ( Figure 5 ). In addition, high-CTC count (≥2) was significantly associated with poor prognosis (Figure 5 ), and the CTC-count was decreased along with tumor resection and/or shrinkage ( Figure S3 ).
These results could indicate that the CTC-count evaluated with the novel CTC-chip system is potentially useful as a biomarker in the diagnosis and treatment of MPM patients, which should be validated in future prospective studies.
In the present study, CTCs appear to be obtained more frequently in patients with sarcomatoid (75%, 3/4) and biphasic (75%, 3/4) subtypes, although the case numbers were small, which might suggest that sarcomatoid and biphasic subtypes are associated with aggressive tumor behavior representing frequent micrometastases. In our previous study using CellSearch, 11 CTCs were detected in similar proportions of patients according to histologic subtypes Figure 2 ). Podoplanin is a transmembrane receptor glycoprotein that is highly expressed on cells of mesothelial origin. 17 The majority (90%-100%) of mesotheliomas show positive staining of podoplanin and it is a most useful marker for the pathological diagnosis. 18 However, Ordóñez reported that podoplanin expression was negative in all sarcomatoid mesothelioma cases (n = 4) whereas podoplanin expression was positive in the majority to 96 hours at room temperature. 6, 7, 11 For the CTC test with the novel CTC-chip, the optimal pre-analytical conditions for longterm storage and shipment shall be explored in future studies.
Finally, molecular profiling of CTCs is essential for further clin- In conclusion, the novel CTC-chip enabled sensitive EpCAMindependent detection of CTCs in MPM patients, which provided not only a significant diagnostic performance in discrimination of "unresectable" patients but also a significant prognostic value.
Future prospective studies are warranted to validate the results.
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